Changes in adhesion molecule expression and function in B-cell chronic lymphocytic leukaemia after in vitro interferon-alpha stimulation.
Peripheral blood mononuclear cells (PBMCs) from 10 B-CLL patients were investigated after 24 hours of in vitro interferon-alpha (IFN-alpha) stimulation. The constitutional expression of the L-selectins (LECAM-1), LFA-1/CD11a, VLA alpha-4/CDw49d and ICAM-1/CD54 adhesion molecules was detected, and changes in their density after IFN-alpha stimulation were compared to results obtained by the high endothelial venule (HEV)-binding assay and a carbohydrate (phosphonomannan core polysaccharide: PPME and fucoidin) immobilization test. The LECAM-1 and ICAM-1 molecules were expressed on the great majority of CLL cells, while the LFA-1 and VLA-4 alpha-chains were expressed by only a small number of cells. Statistically significant changes (p < 0.001) were observed in LECAM-1 antigen density (changes in mean cell fluorescence), as well as in functional tests (HEV-, PPME- and fucoidin-binding; p < 0.01) after in vitro IFN-alpha stimulation. Based on a prior study (Jewell et al., Leukemia 1992: 6: 400-404) and on the present findings, not only an increased expression but also an enhanced function of the L-selectins seem to be well substantiated after IFN-alpha stimulation, which may explain the therapeutic effect of IFN-alpha in reducing the accumulation of leukaemic B cells in the blood. The remarkably high expression of ICAM-1 in this series necessitates further studies to clarify the exact expression rate and role of this molecule.
Csanaky
G
G
Department of Pathology, University Medical School of Pécs, Hungary.
Vass
J A
JA
Ocsovszki
I
I
Milosevits
J
J
Szomor
A
A
Schmelczer
M
M
D000328:Adult; D000368:Aged; D002448:Cell Adhesion / Q000187:drug effects; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000166:cytology; D005260:Female; D006801:Humans; D039001:Integrin alpha Chains; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D019041:L-Selectin; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000378:metabolism*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011134:Polysaccharides / Q000378:metabolism; D016029:Receptors, Very Late Antigen / Q000378:metabolism; D011994:Recombinant Proteins; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured
C063493:CDw49d; D015815:Cell Adhesion Molecules; D039001:Integrin alpha Chains; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D016169:Lymphocyte Function-Associated Antigen-1; D011134:Polysaccharides; D016029:Receptors, Very Late Antigen; D011994:Recombinant Proteins; D018799:Intercellular Adhesion Molecule-1; D019041:L-Selectin; C007789:fucoidan; D013755:Tetradecanoylphorbol Acetate